Oral glucocorticoids raise risk of bladder cancer
- PDF / 141,314 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 88 Downloads / 206 Views
1
Oral glucocorticoids raise risk of bladder cancer Glucocorticoid use appears to elevate patient risk of bladder cancer, according to a study published in the British Journal of Cancer. Researchers collected information on 786 eligible bladder-cancer cases and 1083 eligible control cases through personal interviews, the New Hampshire State Department of Health and Human Services rapid reporting Cancer Registry, the New Hampshire Department of Transportation and the Centres for Medicare and Medicaid Services of New Hampshire. Any glucocorticoid use was associated with an increased risk of bladder cancer versus no use: elevated risk was statistically significant for oral (OR 1.78; 95% CI 1.15, 2.76), but not inhaled (1.52; 0.92, 2.51) routes of administration. Interestingly, amongst patients who had taken oral glucocorticoids, risk was only significantly elevated for those who had taken these medications for ≤ 2 years, though few patients in the study had taken medications for longer than this. Patients taking prednisone who had a maximum daily dose of ≥ 50 mg were found to have elevated odds of bladder cancer relative to controls (OR 4.21; 95% CI 1.12, 15.15), but the same was not true for those with a maximum daily dose of 10–49mg, or < 10mg of this drug. Dietrich K, et al. Glucocorticoid therapy and risk of bladder cancer. British Journal 801129916 of Cancer 101: 1316-1320, No. 8, 20 Oct 2009
0114-9954/10/1283-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 9 Jan 2010 No. 1283
Data Loading...
